Luye Pharma Group Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2014-04-28

Employees: 5.2K

Market Cap: -

Website: http://www.luye.cn

Clinical Trials

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Phase 1

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: Risperdal® Consta®
Drug: LY03004

First Posted Date: 2014-07-10

Last Posted Date: 2015-06-18

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 16

Registration Number: NCT02186769

Locations: 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange County, California, United States
🇺🇸
Community Clinical Research Inc, Austin, Texas, United States

Bioavailability of LY03004 and Risperdal® Consta®

Phase 1

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: LY03004
Drug: Risperdal® Consta®

First Posted Date: 2014-03-19

Last Posted Date: 2015-03-04

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 108

Registration Number: NCT02091388

Locations: 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange, California, United States
🇺🇸
Collaborative Neuroscience Network LLC, Long Beach, California, United States
🇺🇸
Compass Research, Leesburg, Florida, United States

and more 6 locations

Safety, Tolerability and Pharmacokinetics Study of LY03005

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY03005
Drug: Pristiq
Drug: Placebo
Other: Meal

First Posted Date: 2014-02-05

Last Posted Date: 2014-11-10

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 88

Registration Number: NCT02055300

Locations: 🇺🇸
Medpace, Cincinnati, Ohio, United States

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: LY03003
Drug: Neupro

First Posted Date: 2014-02-05

Last Posted Date: 2015-10-21

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 39

Registration Number: NCT02055274

Locations: 🇺🇸
Collaborative Neuroscience Network LLC, Long Beach, California, United States
🇺🇸
West Georgia Sleep Disorders Center and Neurology Associates, Douglasville, Georgia, United States
🇺🇸
Quest Research Institute, Bingham Farms, Michigan, United States

and more 2 locations

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder

Phase 1

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Drug: LY03004

First Posted Date: 2014-02-05

Last Posted Date: 2014-11-10

Lead Sponsor: Luye Pharma Group Ltd.

Target Recruit Count: 36

Registration Number: NCT02055287

Locations: 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange, California, United States
🇺🇸
Community Clinical Research Inc, Austin, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy